MARKET

OMER

OMER

Omeros
NASDAQ
9.88
-0.42
-4.08%
Pre Market: 10.26 +0.38 +3.85% 04:11 03/30 EDT
OPEN
10.40
PREV CLOSE
10.30
HIGH
10.41
LOW
9.86
VOLUME
260
TURNOVER
0
52 WEEK HIGH
17.65
52 WEEK LOW
2.950
MARKET CAP
700.50M
P/E (TTM)
-4.8967
1D
5D
1M
3M
1Y
5Y
1D
Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more
Seeking Alpha · 1d ago
Omeros Has Been Quietly Burning Through Cash. This Week, the Story Either Changes or It Doesn't.
Barchart · 2d ago
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results
Reuters · 4d ago
Press Release: Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Dow Jones · 4d ago
Weekly Report: what happened at OMER last week (0316-0320)?
Weekly Report · 03/23 09:50
Omeros to host EBMT industry session on TA-TMA treatment advances
Reuters · 03/21 07:23
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Barchart · 03/21 02:23
Weekly Report: what happened at OMER last week (0309-0313)?
Weekly Report · 03/16 09:50
More
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.